Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01747798 |
Recruitment Status :
Completed
First Posted : December 12, 2012
Last Update Posted : August 2, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Recurrent Fallopian Tube Cancer Recurrent Ovarian Epithelial Cancer Recurrent Primary Peritoneal Cavity Cancer | Drug: auranofin Other: laboratory biomarker analysis | Early Phase 1 |
PRIMARY OBJECTIVES:
I. To demonstrate the feasibility of conducting a 10-patient pilot study in asymptomatic ovarian cancer patients with cancer antigen (CA 125) elevation.
SECONDARY OBJECTIVES:
I. To explore whether oral gold therapy either stabilizes or lowers the CA 125 level and maintains patients in an asymptomatic state and to provide descriptive data on tumor response and duration of response.
II. To acquire qualitative data on patients' perceptions of learning of CA 125 elevation.
III. To explore whether immunohistochemical staining for PKC iota expression in resected tumor samples appears to be associated with clinical outcomes with auranofin.
OUTLINE:
Patients receive auranofin orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 2 years.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Pilot Trial to Evaluate the Feasibility Auranofin (Ridaura®) for Asymptomatic Patients With First-Recurrence Epithelial Ovarian Cancer |
Actual Study Start Date : | November 2, 2012 |
Actual Primary Completion Date : | January 10, 2014 |
Actual Study Completion Date : | April 6, 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (auranofin)
Patients receive auranofin PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Drug: auranofin
Given PO
Other Name: Ridaura Other: laboratory biomarker analysis Correlative studies |
- Feasibility of conducting a 10-patient pilot study in asymptomatic ovarian cancer patients using CA 125 elevation [ Time Frame: Up to 2 years ]To demonstrate the feasibility of conducting a 10-patient pilot study in asymptomatic ovarian cancer patients with CA 125 elevation. This study could potentially serve as a paradigm to investigate agents that might eventually be used as maintenance therapy in patients at high risk for recurrent disease.
- Immunohistochemical staining for PKCt expression in resected tumor samples with Auranofin [ Time Frame: up to 2 years ]To explore whether immunohistochemical staining for PKCt expression in resected tumor samples appears to be associated with clinical outcomes with Auranofin.
- Patients' perceptions of learning of CA 125 elevation [ Time Frame: up to 2 years ]
- Oral gold therapy influence on the CA 125 levels [ Time Frame: 2 years ]To explore whether oral gold therapy either stabilizes or lowers the CA 125 level and maintains patients in an asymptomatic state and to provide descriptive data on tumor response and duration of response.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histological or cytological confirmation of epithelial ovarian, primary peritoneal, or fallopian cancer from any previous time point
- Completion of initial therapy of epithelial ovarian, primary peritoneal, or fallopian cancer from any previous time point (includes completion of surgery and/or followed by post-operative chemotherapy including maintenance) with no subsequent treatment for progressive disease
- An increase in serum CA 125 level, as defined as follows: 1) normalization of the CA 125 during first-line chemotherapy followed by an increase of >= 100 units/mL; OR 2) normalization of the CA 125 during first-line chemotherapy followed by a doubling of the CA 125 beyond the upper limit of normal with a confirmatory measurement within a period of 4 weeks or less that shows the same or higher CA 125 level
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
- Absolute neutrophil count (ANC) >= 1500
- Platelets (PLT) >= 100,000
- Hemoglobin (HgB) > 9.0 g/dL
- Bilirubin < 1.5 x upper limit of normal (ULN)
- Creatinine within institutional normal limits
- Negative urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Willingness to be interviewed by telephone about CA 125 elevation
- Able to provide informed written consent
- Willing to provide tissue blocks for correlative research purposes (please note that if tissue blocks are unavailable, the patient will still be eligible provided they meet all other eligibility criteria)
Exclusion Criteria:
- Co-morbid systemic illnesses or other severe concurrent disease, which in the judgment of the treating oncologist, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- Symptoms (other than anxiety, depression, or other psychological symptoms) that, in the opinion, of the treating oncologist are a direct result of cancer recurrence; (examples of symptoms that would preclude enrollment include unintentional weight loss and new abdominal pain)
- Receiving any other prescribed therapy treatment for ovarian cancer
-
Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:
- Pregnant women
- Nursing women
- Women of childbearing potential who are unwilling to employ adequate contraception

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01747798
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 |
Study Chair: | Aminah Jatoi, M.D. | Mayo Clinic |
Responsible Party: | Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT01747798 |
Other Study ID Numbers: |
MC1162 NCI-2012-02207 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) |
First Posted: | December 12, 2012 Key Record Dates |
Last Update Posted: | August 2, 2019 |
Last Verified: | October 2018 |
Fallopian Tube Neoplasms Carcinoma, Ovarian Epithelial Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Fallopian Tube Diseases Adnexal Diseases Carcinoma |
Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Ovarian Neoplasms Endocrine Gland Neoplasms Ovarian Diseases Endocrine System Diseases Gonadal Disorders Auranofin Antirheumatic Agents |